<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01999101</url>
  </required_header>
  <id_info>
    <org_study_id>PHS-Px-104-II-01</org_study_id>
    <nct_id>NCT01999101</nct_id>
  </id_info>
  <brief_title>Safety Pilot Study of Farnesoid X Receptor (FXR) Agonist in Non-alcoholic Fatty Liver Disease (NAFLD) Patients</brief_title>
  <official_title>A Safety Pilot Study of Px-104 in Non-alcoholic Fatty Liver Disease (NAFLD) Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Phenex Pharmaceuticals AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Phenex Pharmaceuticals AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary aim of the study is to evaluate the safety and tolerability of Px-104 in NAFLD&#xD;
      patients and to assess the influence of Px-104 on hepatic fat.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>28 days</time_frame>
    <description>Analysis of clinical chemistry, hematology, and assessment of clinical signs and adverse events over 28 days. Change day 28 vs. day 1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of hepatocellular lipid content</measure>
    <time_frame>day 1 and day 28</time_frame>
    <description>Measurement of hepatic fat (%) by Magnetic resonance spectroscopy (MRS), change day 28 vs. day 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in oral glucose tolerance test (oGTT)</measure>
    <time_frame>baseline and day 27</time_frame>
    <description>Measurement of plasma glucose level (mg/dL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in fibroblast growth factor 19 (FGF-19)</measure>
    <time_frame>days 1, 7, 14, 21 and 28</time_frame>
    <description>Measurement by ELISA (pg/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in plasma bile acid concentration</measure>
    <time_frame>days 1, 7, 14, 21, and 28.</time_frame>
    <description>Assessment by LC-MS/MS (µmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of Px-104 and conjugates</measure>
    <time_frame>day 1 and day 28</time_frame>
    <description>Measurement by LC-MS/MS (ng/mL). AUC, Cmax and other pk parameters</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Changes in the Saccharose-Lactulose-Mannitol + Sucralose (SLM+S) Test to evaluate the intestinal permeability</measure>
    <time_frame>baseline and day 27</time_frame>
    <description>Measurement of urinary concentrations of Saccharose, Lactulose, Mannitol and Sucralose by HPLC</description>
  </other_outcome>
  <other_outcome>
    <measure>Assessment of liver steatosis by CAP-Fibroscan</measure>
    <time_frame>baseline and day 28</time_frame>
    <description>Measurement of hepatic fat (%) by CAP-Fibroscan</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Non Alcoholic Fatty Liver Disease</condition>
  <arm_group>
    <arm_group_label>Px-104</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Px-104 capsules, 5 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Px-104</intervention_name>
    <description>28 days treatment</description>
    <arm_group_label>Px-104</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  NAFLD patients&#xD;
&#xD;
          -  Weight &gt; 65 kg&#xD;
&#xD;
          -  BMI &gt; 25 and &lt; 40&#xD;
&#xD;
          -  Negative blood or urine pregnancy test (for females of childbearing potential)&#xD;
             collected at screening followed by another negative serum pregnancy test collected&#xD;
             within 24 hours prior to the first dose of study drug.&#xD;
&#xD;
          -  Contraception: Female patients must be postmenopausal, surgically sterile, or if&#xD;
             premenopausal, must be prepared to use at least two effective (≤1% failure rate)&#xD;
             method of contraception during the course of the study and for 14 days after the end&#xD;
             of dosing. Male patients with female partners of child bearing potential must be&#xD;
             prepared to use at least two effective methods of contraception with all sexual&#xD;
             partners unless they have had a prior vasectomy&#xD;
&#xD;
          -  Must be willing and able to give written informed consent and agree to comply with the&#xD;
             study protocol.&#xD;
&#xD;
          -  Sinus rhythm in 12-lead ECG&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence of excessive alcohol, drug or substance abuse (excluding marijuana use)&#xD;
             within 1 year of first dose.&#xD;
&#xD;
          -  History or other evidence of a medical condition associated with chronic liver disease&#xD;
             other than.&#xD;
&#xD;
          -  History or other evidence of decompensated liver disease (Child-Pugh Grade B or&#xD;
             higher), coagulopathy, hyperbilirubinemia, hepatic encephalopathy, hypoalbuminemia,&#xD;
             ascites, hepatic encephalopathy, and bleeding from esophageal varices are conditions&#xD;
             consistent with decompensated liver disease.&#xD;
&#xD;
          -  Concomitant intake of fibrates or statins (at least 4-6 weeks before start;&#xD;
             considering half life of medication).&#xD;
&#xD;
          -  Any clinically relevant findings in ECG (identified via 24h-Holter ECG or 12-Lead ECG)&#xD;
             at screening&#xD;
&#xD;
          -  History of any structural cardiac disease.&#xD;
&#xD;
          -  In addition, patients with documented or presumed unstable coronary artery disease,&#xD;
             stable or unstable cardiovascular disease or cerebrovascular disease.&#xD;
&#xD;
          -  One or more of the following conditions: (1) poorly controlled hypertension, OR (2)&#xD;
             screening or baseline blood pressure ≥ 160 mmHg for systolic OR (3) screening or&#xD;
             baseline blood pressure ≥ 100 mmHg for diastolic blood pressure.&#xD;
&#xD;
          -  Type I or II diabetes with HbA1C &gt; 6.5% at screening and/or fasting plasma glucose &gt;&#xD;
             7mmol/L (&gt; 126 mg/dl).&#xD;
&#xD;
          -  History or other evidence of a clinically relevant ophthalmologic disorder due to&#xD;
             diabetes mellitus or hypertension or history or other evidence of severe retinopathy&#xD;
             (e.g., cytomegalovirus, macular degeneration).&#xD;
&#xD;
          -  Known sensibility to any ingredients contained in the investigational medicinal&#xD;
             product (IMP)&#xD;
&#xD;
          -  All conditions that do not allow magentic resonance (MR) assessments&#xD;
&#xD;
          -  History of having received any investigational drug ≤ 3 months and/or 6 x half-life&#xD;
             prior to the first dose of study drug or the expectation that such drugs will be used&#xD;
             during the study. Patients enrolled in this study cannot be enrolled in another study&#xD;
             for either research, diagnostic or treatment purposes.&#xD;
&#xD;
          -  Woman with childbearing potential unless using adequate contraception (see inclusion&#xD;
             criteria); females who are pregnant or breast feeding.&#xD;
&#xD;
          -  History of severe allergic&#xD;
&#xD;
          -  Evidence of an active or suspected cancer, or a history of malignancy within the last&#xD;
             2 years, with the exception of patients with basal cell carcinoma that has been&#xD;
             excised and cured.&#xD;
&#xD;
          -  History of any systemic anti-neoplastic or immunomodulatory treatment (including&#xD;
             supraphysiologic doses of steroids and radiation) 6 months prior to the first dose of&#xD;
             study drug or the expectation that such treatment will be needed at any time during&#xD;
             the study.&#xD;
&#xD;
          -  History of bleeding disorders or anticoagulant use&#xD;
&#xD;
          -  History or other evidence of chronic pulmonary disease associated with functional&#xD;
             limitation.&#xD;
&#xD;
          -  History of uncontrolled severe seizure disorder.&#xD;
&#xD;
          -  Poorly controlled thyroid dysfunction.&#xD;
&#xD;
          -  History of major organ transplantation with an existing functional graft.&#xD;
&#xD;
          -  Any signs of acute infection or inflammation&#xD;
&#xD;
          -  History or other evidence of severe illness, or any other conditions which would make&#xD;
             the patient, in the opinion of the investigator, unsuitable for the study.&#xD;
&#xD;
          -  Any herbal supplements containing silymarin, tocopherol, vitamin C, riboflavins,&#xD;
             proflavins, curcumin. (at least 4-6 months before the study)&#xD;
&#xD;
          -  Positive test at screening for anti-Hepatits A virus (HAV) Immunoglobulin M (IgM),&#xD;
             Hebatitis B surface antigen (HBsAg), Anti-Hepatits B core Antigen Immunglobulin M&#xD;
             antibody (anti-HBc IgM Ab), or anti-HIV Ab.&#xD;
&#xD;
          -  Subjects who have undergone surgery within the last 3 months.&#xD;
&#xD;
          -  Subjects who have had a prior gastrointestinal surgery.&#xD;
&#xD;
          -  Subjects who will be unavailable for the duration of the trial, who are unlikely to be&#xD;
             compliant with the protocol, or who are felt to b unsuitable by the investigator for&#xD;
             any other reason&#xD;
&#xD;
          -  Imprisonment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Trauner, Professor Dr med</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University Vienna</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Division of Gastroenterology and Hepatology, Department of Internal Medicine III</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <study_first_submitted>November 19, 2013</study_first_submitted>
  <study_first_submitted_qc>November 25, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2013</study_first_posted>
  <last_update_submitted>September 28, 2016</last_update_submitted>
  <last_update_submitted_qc>September 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

